Apr 25, 2023 / 06:30PM GMT
Ben Burnett - Stifel Financial Corp. - Analyst
Okay. Welcome, everyone, to our next session. I'm pleased to have Verastem Oncology with us today. It is a company focused developing medicines to treat RAS pathway driven cancers. And we have with us today, CEO, Brian Stuglik. And Brian, I'll pass it over to you for a presentation.
Brian Stuglik - Verastem, Inc. - CEO
Thank you very much, Ben, for hosting today, and I look forward to providing an update on the progress we've been making at Verastem Oncology. Really like to touch upon three things during the presentation. Just a quick overview of the company, a data recap in terms of the most recent data we did that put out earlier this year, and then talk about some upcoming inflection points for the second quarter of this year and the remainder of the year. Obviously, I will be making forward-looking statements today. So I would just refer listeners to our website for our risk factors.
Verastem Oncology is well-positioned to capitalize on what we believe is a very good growth opportunity. Our lead
Verastem Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers